Results 111 to 120 of about 128,389 (322)
Cancer Reports, Volume 8, Issue 6, June 2025.ABSTRACT Background Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re‐introduction of imatinib after a hypersensitivity ...
Maud B. A. van der Kleij +10 more
wiley +1 more source
Haematologica, 2007 The development of resistance to imatinib mesylate may partly depend on high Bcr-Abl-expression levels. Arsenic trioxide (ATO) has Bcr-Abl suppressing activity in vitro.
Heiko Konig +8 more
doaj +1 more source
, 2011 dissertationThe primary cause of chronic myelogenous leukemia (CML) is the presence of the Philadelphia chromosome, resulting in the oncoprotein Bcr-Abl.
Dixon, Andrew S.
core
Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]
, 2008 Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad +4 more
core +1 more source
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients [PDF]
, 1993 Koichi Miyamura +9 more
openalex +3 more sources
Molecular Cancer, 2012 Background Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I ...
Fei Fei +5 more
doaj +1 more source
Combination of \u3cem\u3eBcr-Abl\u3c/em\u3e-specific RNA Interference with lmatinib Treatment in the K-562 Cell Line [PDF]
, 2004 RNA interference (RNAi) involves the specific repression of the translation of a gene through mRNA degradation. Its application has been extended to a variety of studies both in vitro and in vivo.
Baker, Benjamin Eugene
core +1 more source
Elucidation of mechanism of disease resistance and persistence in chronic myeloid leukemia. [PDF]
, 2011 Chronic myeloid leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by the BCR-ABL receptor tyrosine kinase. Imatinib mesylate (IM) is an inhibitor of BCR-ABL and has been approved for the treatment of CML.
Kumari, Ashu
core +1 more source
CarboxyAmido-Triazole Orotate inhibits the growth of Imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis [PDF]
, 2012 Chronic myelogenous leukemia is a myeloproliferative disorder characterized by the t(9:22) (q34:q11) reciprocal chromosomal translocation, resulting in the expression of the chimeric Bcr–Abl oncoprotein with constitutive tyrosine kinase activity ...
ALESSANDRO, Riccardo +5 more
core
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source